一二三四区视频,亚洲少妇熟女色,日本久热无码视频网,欧美国产日韩大尺度,亚洲a视频,久久少妇一区二区,日韩999无码视频,刺激久久久久久久,啊啊啊啊不要啊在线

ChemicalBook >> journal list >> Pharmacological research >>article
Pharmacological research

Pharmacological research

IF: 9.1
Download PDF

Preclinical evaluation of the antitumoral efficacy of Wee1 inhibitor AZD1775 in adrenocortical carcinoma

Published:15 October 2025 DOI: 10.1016/j.phrs.2025.107997 PMID: 41106571
Emma Nozza , Emanuela Esposito , Genesio Di Muro , Sonia Di Bari , Rosa Catalano , Gianluca Lopez , Valentina Vaira , Anna Maria Barbieri , Giusy Marra , Federica Mangili , Donatella Treppiedi , Michele Battistin , Guido Di Dalmazi , Serena Palmieri , Emanuele Ferrante , Giovanna Mantovani , Erika Peverelli

Abstract

Current therapy for advanced adrenocortical carcinoma (ACC) is represented by EDP-M (etoposide, doxorubicin, cisplatin + mitotane), but its efficacy is limited and new approaches are needed. Our previous in vitro findings showed that AZD1775, an inhibitor of the G2/M checkpoint gatekeeper Wee1, reduces proliferation and increases apoptosis in ACC cell models. The compensatory upregulation of Myt1, a Wee1-redundant kinase, has been involved in the onset of AZD1775 resistance in other tumour types. Aim of this study was to investigate in vitro and in vivo the effects of AZD1775 alone or combined with EDP-M, and to explore the onset of molecular mechanisms of resistance. In vitro experiments in human ACC cell line NCI-H295R demonstrated that coincubation of AZD1775 and EDP-M exerted synergistic effects in reducing cell viability and proliferation and additive effects in inhibiting cortisol secretion. In NCI-H295R xenografts in nude mice, AZD1775 demonstrated an antitumor efficacy comparable to EDP-M, without synergistic effects. Myt1 upregulation was observed after Wee1 silencing or inhibition by AZD1775 in NCI-H295R and patient-derived ACC cells, but not in mice tumours after 22-days treatment with AZD1775 and/or EDP-M. Interestingly, Myt1 increase after AZD1775 treatment in primary ACC cells was reverted by EDP-M cotreatment. Overall, our data in in vitro and in vivo preclinical ACC models support AZD1775 as a promising ACC therapeutic option, and its combination with EDP-M as a useful strategy to enhance drug efficacy, reduce cortisol secretion, prevent drug resistance and minimize side effects by reducing the therapeutic dosage.

Substances (16)

Materials
Procduct Name CAS Molecular Formula Supplier Price
Etoposide 33419-42-0 C29H32O13 693 suppliers $9.00-$17300.00
Etoposide 33419-42-0 C29H32O13 693 suppliers $9.00-$17300.00
Etoposide 33419-42-0 C29H32O13 693 suppliers $9.00-$17300.00
Etoposide 33419-42-0 C29H32O13 693 suppliers $9.00-$17300.00
Mitotan 53-19-0 C14H10Cl4 342 suppliers $8.00-$1504.50
Mitotan 53-19-0 C14H10Cl4 342 suppliers $8.00-$1504.50
Mitotan 53-19-0 C14H10Cl4 342 suppliers $8.00-$1504.50
Mitotan 53-19-0 C14H10Cl4 342 suppliers $8.00-$1504.50
MK-1775 955365-80-7 C27H32N8O2 279 suppliers $9.00-$2700.00
MK-1775 955365-80-7 C27H32N8O2 279 suppliers $9.00-$2700.00

Similar articles

IF:8.3

Use of the JAK Inhibitor Ruxolitinib in the Treatment of Hemophagocytic Lymphohistiocytosis.

ACS Applied Materials & Interfaces Camille Keenan, Kim E Nichols,etc Published: 16 February 2021
虞城县| 麟游县| 恩施市| 新源县| 桐乡市| 寿阳县| 罗城| 隆尧县| 河北区| 西峡县| 南靖县| 故城县| 洪雅县| 四子王旗| 平凉市| 绥芬河市| 仁布县| 玉屏| 龙游县| 盐源县| 迁安市| 鸡西市| 武穴市| 武威市| 河西区| 乌拉特中旗| 弋阳县| 西平县| 潮安县| 连云港市| 安庆市| 霍州市| 镇巴县| 宝丰县| 大同县| 桦甸市| 久治县| 韶关市| 齐齐哈尔市| 伊通| 汉阴县|